Effects of survivin interference RNA on non-small cell lung carcinoma

Clinical and Investigative Medicine

Volumn 32, Issue 6, 2009, Pages

  Liu, Guan Feng ^a   Zhao, Qi Gang ^b   Si, Lei ^b   Cao, Yin Guang ^b   Li, Guang Yao ^b   Wang, Le Xin ^c  

^a Wuhan Automobile Polytechnic University   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DNA PRIMERS; GENETIC VECTORS; HUMANS; LENTIVIRUS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 73249128492     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100:751-7.
2. Ikehara M, Oshita F, Kameda Y, et al. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 2002; 9:835-8.
3. Hannon GJ. RNA interference. Nature 2002; 418:244-51.
4. Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 2004; 9:101-11.
5. Pennati M, Binda M, Colella G, et al. Ribozymemediated inhibition of
6. survivin expression increases spontaneous and druginduced apoptosis and decreases the
7. tumorigenic potential of human prostate cancer cells. Oncogene 2004; 23:386-94.
8. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell
9. proliferation by survivin gene targeting. Biol Chem 1998; 273:77-82.
10. Reed JC. The Survivin saga goes in vivo. Clin Invest 2001; 108:965-9.
11. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri D.Therapeutic targeting of
12. the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of
13. tumor-associated angiogenesis. Clin Cancer Res 2003; 9:2683-92.
14. Connell CM, Colnaghi R, Wheatley SP. Nuclear survivin has reduced stability and is not
15. cytoprotective. Biol Chem 2008; 283:3289-96.
16. Asanuma K, Tsuji N, Endoh T, Yagihashi A, Watanabe N. Survivin enhances Fas ligand
17. expression via up-regulation of specificity protein 1-mediated gene transcription in colon
18. cancer cells. Immunol 2004;172:3922-9.
19. Sledz CA, Holko M, de Veer MJ, Silverman R, Williams B. Activation of the interferon
20. system by short interfering RNA. Nat Cell Biol 2003;5:834-9.
21. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L.Gene transfer by lentiviral vectors
22. is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000;25:217-22.
23. Yang CT, Li JM, Weng HH, Li YC, Chen HC, Chen MF. Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human nonsmall cell lung cancer cells. Cancer Gene Ther 2009 Sep 4. doi: 10.1038/cgt.2009.55
24. Yang H, Fu JH, Hu Y, et al. Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells. J Int Med Res 2008; 36:734-47.
25. Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006;15:118:812-20.
26. Yonesaka K, Tamura K, Kurata T, et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int Cancer 2006; 118:812-20.
27. Mescalchin A, Detzer A, Wecke M, Overhoff M, Wunsche W, Sczakiel G.. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioatestimulated delivery. Expert Opin Biol Ther 2007; 7:1531-8.